Mitemcinal

Mitemcinal

Mitemcinal is a gastroprokinetic agent, a type of pharmaceutical drug that enhances gastrointestinal motility by increasing the frequency or strength of contractions in the smooth muscles of the gastrointestinal tract.

Pharmacology

Mitemcinal, also known as GM-611, is a motilin receptor agonist. Motilin is a 22-amino acid peptide hormone secreted by the M cells in the small intestine that stimulates the production of pepsin in the stomach and increases the rate of gastric emptying. By acting as an agonist at the motilin receptor, mitemcinal can stimulate gastrointestinal motility, making it potentially useful in the treatment of various gastrointestinal disorders.

Clinical Uses

Mitemcinal has been investigated for use in the treatment of gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. It may also have potential applications in the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, and other disorders characterized by impaired gastrointestinal motility.

Development and Approval

Mitemcinal was developed by Gotoh Pharmaceutical and has undergone Phase II clinical trials in Japan for the treatment of gastroparesis. However, as of 2021, it has not yet received approval from the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Side Effects

As with all drugs, mitemcinal may cause side effects. In clinical trials, the most commonly reported side effects were abdominal pain and diarrhea. However, these side effects were generally mild and transient.

See Also

• Gastroprokinetic agent
• Motilin
• Gastroparesis
• Gastroesophageal reflux disease
• Functional dyspepsia